Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Registration Number
- NCT00051571
- Lead Sponsor
- Seagen Inc.
- Brief Summary
This randomized phase II clinical trial evaluates the combination of a monoclonal antibody-based drug (SGN-15) with a chemotherapeutic agent compared to chemotherapy given alone in patients with non-small cell lung cancer that has failed at least one prior systemic therapy. The objective of the study is to determine the safety and clinical benefit, as measured by tumor response and quality of life, to the combination regimen.
Monoclonal antibody therapy has been used in other types of cancer to target therapy to the tumor, thereby allowing for the chemotherapeutic agent to have a lesser effect on normal, healthy tissue.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (9)
University of Chicago
🇺🇸Chicago, Illinois, United States
Florida Cancer Specialists
🇺🇸Fort Myers, Florida, United States
Virginia Mason Research Center
🇺🇸Seattle, Washington, United States
Kaiser Permanente
🇺🇸Portland, Oregon, United States
Bendheim Cancer Center
🇺🇸Greenwich, Connecticut, United States
UCLA Medical Center
🇺🇸Los Angeles, California, United States
Providence Health System
🇺🇸Portland, Oregon, United States
Hematology Oncology Associates of the Treasure Coast
🇺🇸Port St. Lucie, Florida, United States
Madigan Army Medical Center
🇺🇸Tacoma, Washington, United States